Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL

Vaxcyte, Inc.

VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.
Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.
Four VAX-24-unique serotypes met all target criteria at all doses evaluated.
Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).
Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.